Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06489678

Benefit of Cone-beam CT and Robotic-Assisted Bronchoscopy During Bronchoscopy

This randomized controlled trial evaluates the integration of cone-beam computed tomography (CBCT) and robotic-assisted bronchoscopy (RAB) for diagnosing pulmonary lesions, hypothesizing improved diagnostic yield compared to traditional methods. The trial involves 2 study arms (2x46 lesions) over 24 months with 12 months of follow-up and the diagnostic yield (ATS 2024 criteria) as the primary endpoint.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

About this study

This randomized-controlled-trial, classified as Category A under Art 6 ClinO-MD, investigates the potential benefits of integrating cone-beam computed tomography (CBCT) and robotic-assisted bronchoscopy (RAB) into clinical practice for diagnosing pulmonary lesions. The study aims to enhance biopsy accuracy and safety by utilizing 3-dimensional reconstructions and increased flexibility of the bronchoscope tip. It targets two main clinical scenarios: peripheral lung lesions (PPLs) and other lung diseases requiring tissue biopsies. The hypothesis is that CBCT and RAB will significantly improve diagnostic yield compared to traditional 2D fluoroscopy techniques and endobronchial ultrasound.

The trial will involve 300 participants in the overall observational study, with a nested randomized controlled trial (RCT) for specific lesion types, targeting 2x46 lesions for 2 study arms i) usual care, ii) CBCT and RAB .

Primary endpoints include procedure time for the overall trial and diagnostic yield (ATS 2024 criteria) for the nested RCTs, analyzed via Pearson's Chi-squared test and multivariable logistic regression. Inclusion criteria encompass patients aged 18 or older, scheduled for bronchoscopy, with necessary pre-interventional exams and informed consent. Exclusion criteria include inability to tolerate the procedure, pregnancy, previous trial randomization, and specific lung conditions. The study's recruitment phase spans 24 months, with a 12-month follow-up, running from July 2024 to July 2027.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged >18 years
  • Scheduled for bronchoscopy in order to obtain at least 1 specimen(s) of the lung via transbronchial biopsy
  • Necessary periinterventional laboratory examinations and other examinations needed for the bronchoscopy
  • Informed consent

Exclusion criteria

  • Not able to tolerate procedure (bronchoscopy or apnea for CBCT)
  • Previous randomization to an arm of the present trial
  • Endobronchial lesion causing lobar atelectasis
  • Inability or contraindications to undergo bronchoscopy (e.g. severe cardiopulmonary diseases, coagulation disorders, intolerance to anesthesia or endoscopic operation, psychiatric disorders, or severe neurosis)
  • Pregnant or lactating women

For nested RCTs (Trial A + B):

  • A: At least 1 peripheral lung lesion suspicious for lung cancer, beyond the visual range of the bronchoscope, rounded or irregular opacity, may be well or poorly defined, measuring ≤3 cm in diameter of the short axis (in CT scan)
  • B:At least 1 peripheral target lung lesion of any kind beyond the visual range of the bronchoscope (measuring >3 cm in diameter of the short axis and/or with an interstitial pattern)

Treatment and study plan

Robotic Assisted Bronchoscopy

Diagnostic Test

Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.

Other names: Cios Spin (Siemens) and Ion endoluminal system (Intuitive)

Primary outcomes

  1. Diagnostic Yield

    Time frame: Including a 12-month follow-up (clinical data)

    ATS 2024 consensus criteria

Secondary outcomes

  1. Radiation exposure

    Time frame: During Intervention

    Dose area product

  2. Safety profile

    Time frame: During Intervention

    Rates of complications (bleeding, pneumothorax, pneumonia)

  3. Diagnostic accuracy for milignancy

    Time frame: Including a 12-month follow-up (clinical data)

    True positives + true negatives / true positives + true negatives + false positives + false negatives

  4. Quality of biopsies

    Time frame: During Intervention

    Number of malignant cells, suitability rates for further molecular pathological testing

  5. Navigation success

    Time frame: During Intervention

    Anatomical confirmation of the position of the catheter in front or within the lesion as confirmed by r-EBUS or CBCT [not fluoroscopy]

Other outcomes

  1. Procedure Duration

    Time frame: During Intervention

    Time of the whole procedure

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

The Benefit of Cone-beam Computed Tomography and Robotic Assisted Bronchoscopy for the Diagnosis of Peripheral Pulmonary Lesions and Other Lung Disease Requiring Lung Biopsy: An Open-label, Randomized, Controlled Trial.

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
Jul 8, 2024
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.